Evidence map›Paper›PMID 25985992›Full record

Trial reportMalaria journal2015

Costs and cost-effectiveness of a large-scale mass testing and treatment intervention for malaria in Southern Province, Zambia.

Kafula Silumbe, Joshua O Yukich, Busiku Hamainza, Adam Bennett, Duncan Earle, Mulakwa Kamuliwo, Richard W Steketee, Thomas P Eisele, John M Miller

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Malaria journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 4 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Costs and Cost-Effectiveness of Malaria Control Interventions: A Systematic Literature Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021
    Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Kafula SilumbeMalaria Control and Evaluation Partnership in Africa (PATH-MACEPA), Lusaka, Zambia. ksilumbe@path.org.
Joshua O YukichCenter for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA. jyukich@tulane.edu.
Busiku HamainzaNational Malaria Control Centre, Lusaka, Zambia. bossbusk@gmail.com.
Adam BennettMalaria Elimination Initiative, University of California San Francisco, San Francisco, USA. Adam.Bennett@ucsf.edu.
Duncan EarleMalaria Control and Evaluation Partnership in Africa (PATH-MACEPA), Lusaka, Zambia. dearle@path.org.
Mulakwa KamuliwoNational Malaria Control Centre, Lusaka, Zambia. mkamuliwo@yahoo.co.uk.
Richard W SteketeeMalaria Control and Evaluation Partnership in Africa (PATH-MACEPA), Lusaka, Zambia. rsteketee@path.org.
Thomas P EiseleCenter for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA. teisele@tulane.edu.
John M MillerMalaria Control and Evaluation Partnership in Africa (PATH-MACEPA), Lusaka, Zambia. jmiller@path.org.
National HIV/AIDS/STI/TB Council · ZMTulane University · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA cluster, randomized, control trial of three dry-season rounds of a mass testing and treatment intervention (MTAT) using rapid diagnostic tests (RDTs) and artemether-lumefantrine (AL) was conducted in four districts in Southern Province, Zambia.

methodsData were collected on the costs and logistics of the intervention and paired with effectiveness estimated from a community randomized control trial for the purpose of conducting a provider perspective cost-effectiveness analysis of MTAT vs no MTAT (Standard of Care).

resultsDry-season MTAT in this setting did not reduce malaria transmission sufficiently to permit transition to a case-investigation strategy to then pursue malaria elimination, however, the intervention did substantially reduce malaria illness and was a highly cost-effective intervention for malaria burden reduction in this moderate transmission area. The cost per RDT administered was estimated to be USD4.39 (range: USD1.62-13.96) while the cost per AL treatment administered was estimated to be USD34.74 (range: USD3.87-3,835). The net cost per disability adjusted life year averted (incremental cost-effectiveness ratio) was estimated to be USD804.

conclusionsThe intervention appears to be highly cost-effective relative to World Health Organization thresholds for malaria burden reduction in Zambia as compared to no MTAT. However, it was estimated that population-wide mass drug administration is likely to be more cost-effective for burden reduction and for transmission reduction compared to MTAT.

Indexed as

AntimalarialsArtemisininsDiagnostic Tests, RoutineEthanolaminesFluorenesMalariaMass ScreeningArtemether, Lumefantrine Drug CombinationCost-Benefit AnalysisDrug CombinationsHumansZambiaAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsDrug CombinationsEthanolaminesFluorenes

Identifiers

PMID25985992
PMCPMC4490652
OpenAlexW1542339819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.